NCT00226369View on ClinicalTrials.gov

Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

December 31, 1997

Study Completion Date

June 30, 2001

Conditions
Congenital Heart Defects
Interventions
DRUG

CY-1503

Trial Locations (1)

02115

Children's Hospital Boston, Boston

All Listed Sponsors
lead

Boston Children's Hospital

OTHER

NCT00226369 - Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery | Biotech Hunter | Biotech Hunter